MM120
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anxiety Generalized
Conditions
Anxiety Generalized
Trial Timeline
Aug 24, 2022 → Nov 27, 2023
NCT ID
NCT05407064About MM120
MM120 is a phase 2 stage product being developed by Definium Therapeutics for Anxiety Generalized. The current trial status is completed. This product is registered under clinical trial identifier NCT05407064. Target conditions include Anxiety Generalized.
What happened to similar drugs?
6 of 20 similar drugs in Anxiety Generalized were approved
Approved (6) Terminated (1) Active (13)
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05407064 | Phase 2 | Completed |
| NCT05200936 | Phase 2 | Completed |
Competing Products
20 competing products in Anxiety Generalized